Prelude Therapeutics Incorporated

PRLD

US74065P1012

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
4.07 ^USD	+0.74%		+9.41%	-4.68%

Apr. 10	Bryant D. Lim to Serve as Principal Financial Officer and Principal Accounting Officer of Prelude Therapeutics Incorporated	CI
Apr. 10	Prelude Therapeutics Incorporated Announces Chief Financial Officer Changes	CI

Prelude Therapeutics Incorporated announced that it has received $24.999997 million in funding

December 12, 2023

On December 13, 2023, Prelude Therapeutics Incorporated closed the transaction.

Latest news about Prelude Therapeutics Incorporated

Bryant D. Lim to Serve as Principal Financial Officer and Principal Accounting Officer of Prelude Therapeutics Incorporated	Apr. 10	CI
Prelude Therapeutics Incorporated Announces Chief Financial Officer Changes	Apr. 10	CI
Transcript : Prelude Therapeutics Incorporated Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 03:05 PM	Mar. 13
JMP Securities Starts Prelude Therapeutics With Market Outperform Rating, $7 Price Target	Mar. 13	MT
HC Wainwright Downgrades Prelude Therapeutics to Neutral From Buy, Price Target is $5	Feb. 20	MT
Prelude Therapeutics Shares Surge Following Shelf Registration	Feb. 16	MT
Prelude Therapeutics Incorporated Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15	CI
Transcript : Prelude Therapeutics Incorporated - Special Call	Feb. 12
Morgan Stanley Downgrades Prelude Therapeutics to Underweight From Equalweight, Cuts Price Target to $4 From $10	Dec. 19	MT
Prelude Therapeutics Incorporated(NasdaqGS:PRLD) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Prelude Therapeutics Incorporated announced that it has received $24.999997 million in funding	Dec. 12	CI
Prelude Therapeutics Incorporated announced that it expects to receive $24.999997 million in funding	Dec. 10	CI
HC Wainwright Trims Prelude Therapeutics' Price Target to $5 From $6, Keeps Buy Rating	Nov. 07	MT
Prelude Therapeutics Incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 01	CI
HC Wainwright Adjusts Price Target on Prelude Therapeutics to $6 From $17, Keeps Buy Rating	23-10-19	MT
Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference	23-10-14	CI
Transcript : Prelude Therapeutics Incorporated Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 04:55 PM	23-09-12
Certain Common Stock of Prelude Therapeutics Incorporated are subject to a Lock-Up Agreement Ending on 17-AUG-2023.	23-08-16	CI
Certain Restricted Stock Units of Prelude Therapeutics Incorporated are subject to a Lock-Up Agreement Ending on 17-AUG-2023.	23-08-16	CI
Certain Stock Options of Prelude Therapeutics Incorporated are subject to a Lock-Up Agreement Ending on 17-AUG-2023.	23-08-16	CI
Barclays Adjusts Price Target on Prelude Therapeutics to $5 From $7, Maintains Equalweight Rating	23-08-04	MT
Prelude Therapeutics Incorporated Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell Small Cap Comp Value Index	23-06-23	CI
Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell 3000 Index	23-06-23	CI
Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell 3000E Index	23-06-23	CI

Chart Prelude Therapeutics Incorporated

Duration

Period

More charts

Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT3645. PRT3789 is a highly selective degrader of SMARCA2 protein, which along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT3645 is a brain and tissue penetrant molecule that potently targets CDK4/6 with a biased selectivity for CDK4. PRT2527 is designed to be a potent and selective CDK9 inhibitor. Its MCL1 candidate, PRT1419, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1.

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

4.07 USD

Average target price

4.75 USD

Spread / Average Target

+16.71%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PRELUDE THERAPEUTICS INCORPORATED	-4.68%	223M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research